Protalix BioTherapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with NYSE American-listed common stock and a business built around recombinant therapeutic proteins produced through ProCellEx®. The company’s Form 8-K reports cover operating results, financial condition, business and clinical updates, corporate presentations, stockholder communications and regulatory events involving Elfabrio®.
Protalix’s proxy materials describe board governance, executive compensation, equity awards and shareholder voting matters. Its regulatory disclosures also identify material event reporting around European regulatory actions for Elfabrio, collaboration-related communications with commercialization partners, and the capital-market status of its common stock.
Director Christian Elze acquired equity in Protalix BioTherapeutics (PLX) on 09/03/2025. The Form 4 reports an acquisition of 7,500 restricted shares of common stock that are registered in the name of a trustee to qualify for Israeli tax treatment, with the restricted shares vesting in 12 equal quarterly installments beginning on the grant date. The filing also shows an award of stock options to purchase 15,000 shares at an exercise price of $1.64, exercisable through 09/03/2035, with the options vesting in 12 equal quarterly installments commencing on the grant date. Following the reported transactions, the reporting person beneficially owns 7,500 common shares (indirect) and 15,000 options (direct).
Aharon Schwartz, a director of Protalix BioTherapeutics, Inc. (PLX), reported equity awards and option grants on 09/03/2025. He was awarded 7,500 restricted shares of common stock that vest in 12 equal quarterly installments and are held indirectly by a trust to qualify for Israeli tax benefits. He disposed of 303,000 shares on the same date. He was also granted stock options to buy 15,000 shares at a $1.64 exercise price, exercisable beginning 09/03/2025 and expiring 09/03/2035, with the underlying shares vesting in 12 equal quarterly installments. The reporting notes additional outstanding options totaling 151,676 shares across prior grants at various exercise prices and expirations.
Protalix BioTherapeutics (PLX) director Ben Zvi Shmuel received equity awards on 09/03/2025. The filing reports 7,500 restricted shares granted under the companys amended 2006 Stock Incentive Plan, held indirectly by trust to qualify for Israeli Section 102 tax benefits, and 15,000 stock options with a $1.64 exercise price that expire on 09/03/2035. The restricted shares and options each vest in 12 equal quarterly installments commencing on the grant date. The filing also discloses additional outstanding options with various exercise prices and expiration dates.
Bar-Shalev Amos, a director of Protalix BioTherapeutics, Inc. (PLX), reported transactions on 09/03/2025. He was awarded 7,500 restricted shares under the companys Amended and Restated 2006 Stock Incentive Plan; those shares are registered in a trustee to meet Israeli Section 102 requirements and vest in 12 equal quarterly installments, with accelerated vesting on a corporate transaction or change in control. He also received a grant of 15,000 stock options with a $1.64 exercise price exercisable from 09/03/2025 and expiring 09/03/2035. Following the transactions the reporting person beneficially owns 7,500 shares indirectly and directly holds 15,000 option-based shares. The Form notes a separate disposition of 168 shares. The filing was signed by an attorney-in-fact on 09/04/2025.
Naos Yaron, Sr. VP, Operations of Protalix BioTherapeutics (PLX), reported transactions dated 09/03/2025. He was awarded 25,000 restricted shares under the company's Amended and Restated 2006 Stock Incentive Plan, which vest in 12 equal quarterly installments and accelerate on a corporate transaction or change in control. The shares are registered in the name of a trustee to comply with Israeli tax rules.
On the same date he was granted a stock option to buy 50,000 shares at $1.64 per share exercisable through 09/03/2035 with a similar 12-quarter vesting schedule. The Form 4 also reports a sale of 7,112 shares and shows 225,817 shares beneficially owned following the transactions (held indirectly by a trust).
Protalix BioTherapeutics (PLX) reporting person Dror Bashan, who is President, CEO and a director, recorded equity awards and a disposition on 09/03/2025. He was granted 195,000 restricted shares under the company’s amended 2006 Stock Incentive Plan that vest in 12 equal quarterly installments and are registered in a trustee for Israeli tax purposes. The filing also shows a grant of a stock option covering 340,000 shares with a $1.64 exercise price, exercisable immediately and expiring 09/03/2035, and a reported disposition of 132,516 common shares. The restricted shares and options include accelerated vesting on a corporate transaction or change in control as described in the Plan.
Protalix BioTherapeutics (PLX) Form 3: Gilad Mamlok, Sr. VP and CFO, filed an initial Form 3 reporting derivative securities on 08/24/2025. The filing shows a stock option exercisable beginning 07/20/2035 covering 597,990 shares of common stock at an exercise price of $1.45 per share. The option is held directly and vests in 12 equal quarterly installments commencing on the grant date, with accelerated vesting provisions upon a corporate transaction or change in control under the company’s amended 2006 Stock Incentive Plan. The form is signed by Gilad Mamlok on 08/25/2025.
Protalix BioTherapeutics, Inc. entered into a new letter agreement on August 22, 2025 amending its existing at-the-market equity offering program with H.C. Wainwright & Co., LLC. The change updates the prior sales agreement so that future at-the-market sales of common stock can be made under Protalix’s new shelf registration statement on Form S-3 (Registration No. 333-286802).
The company also filed as exhibits the amendment itself and a legal opinion from its counsel, Mayer Brown LLP, confirming the legality of the shares that may be sold under this updated program.
Protalix BioTherapeutics (PLX) filed a prospectus supplement for potential offerings of equity, preferred stock, debt securities and warrants. The document emphasizes numerous risk factors including commercialization risks for its approved product Elfabrio (pegunigalsidase alfa-iwxj), which carries an FDA boxed warning; potential operational disruptions from regional hostilities in Israel and related supply-chain and regulatory impacts; and counterparty risks such as Fiocruz’s compliance with a supply and technology transfer agreement.
The prospectus also details standard offering mechanics to be disclosed per series (pricing, interest, redemption, conversion, covenants and events of default), reserved shares under its stock plan (7,130,994 exercisable options at $1.80 and up to 4,410,713 additional reserved shares), and SEC documents incorporated by reference including the 2024 Annual Report and several 2025 quarterly and current reports.
Protalix BioTherapeutics filed a pre-effective amendment to its Form S-3 as an exhibits-only filing to include an updated auditor consent from Kesselman & Kesselman (a PwC Israel member firm). The amendment consists solely of the facing page, an explanatory note, Item 16 with the exhibit index, the signature page and the filed exhibits; the prospectus is unchanged and has been omitted. The filing includes signatures by Dror Bashan and other officers and directors.